Aeterna Zentaris has entered into binding pharma partnering agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide product.
The principal effect of such pharma partnering agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA.
Subject to the satisfaction of customary closing conditions, Aeterna Zentaris would receive a one-time payment of €2.5 million, or approximately $3.2 million and certain other payments.
In addition, the Company has also entered into a transitional services agreement with Merck KGaA under which the Company will, during a 36-month period, provide various transition services to assist Merck KGaA in assuming responsibility for the manufacturing of Cetrotide in consideration for the payment of a monthly fee to the Company throughout such period.
Cetrotide is used to regulate hormone responses in women undergoing infertility treatment.
Merck Serono, a leader in the field of fertility treatments, currently markets Cetrotide worldwide, excluding Japan.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Merck KgaA / Merck Serono
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity